Global Viral Testing

Viral Testing Comprehensive Study by Type (Direct Fluorescent Antibody (DFA) Test, Immunochromatographic Assay, RT-PCR-Based Test, Agglutination Assay, Flow-Through Assay/Solid-Phase Assay), Application (Individual, Commercial), End-User (Laboratories, Hospitals, Home Care Settings, Academic Institutes), Virus Type (Influenza, Hepatitis, HIV, Measles, Rubella, Others) Players and Region - Global Market Outlook to 2027

Viral Testing Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Viral Testing Market Overview:
The global virus testing market is hereby expected to grow with a highly robust CAGR over the forecasted period due to the increasing consumer preference for self-diagnostic techniques. In addition, to these many of the leading companies are at present continuously investing in the research and development sector so as to develop new testing kits for the various viral diseases. Viral infections can be diagnosed by testing blood, the body fluids, or samples from the infected area of the body that are further examined using an electron microscope. Viral infections like measles and rubella are usually diagnosed on the basis of their symptoms. Some of the highly serious viral infections are diagnosed by the means of examining the blood or body fluids. The prevalence of infectious diseases has increased significantly over the past ten years. The growing preference for self-diagnosis of viral diseases and the increased detection of new infectious viruses are important factors that should drive the market for diagnostic kits for virus tests in the near future. However, complex regulatory scenarios regarding the approval of diagnostic tests for viral infections and rising healthcare costs are expected to limit the market in the forecast period.

AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Historical Period2017-2021
UnitValue (USD Million)
Key Companies ProfiledRoche Holding AG (Switzerland), Agilent Technologies (United States), Thermo Fisher Scientific (United States), QIAGEN International (Netherlands), Lonza Group AG (Switzerland), Wuxi Pharmatech (Cayman), Merck (United States), Eurofins Scientific (Luxembourg), General Electric (United States), Danaher Corporation (United States), Bio-Rad Laboratories (United States) and BD (United States)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Growth Drivers
  • Rising Prevalence of the Disease across the Globe
  • Increasing Demand for More Rapid Diagnostic Test Kits for Influenza
  • Rising Prevalence of Viral Diseases

Roadblocks
  • Complex Regulatory Scenario Regarding the Approval for Diagnostic Tests for Viral Infections
  • Increasing Health Care Costs

Opportunities
  • Funding By Public and Private Players for Research and Development of Novel Virus Diagnostic Techniques
  • Growth in Favorable Reimbursement Policies
  • Government Participation in the Prevention and Control of Infectious Diseases

Challenges
  • Unawareness about Viral Testing in Under Developed Regions


Competitive Landscape:
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Roche Holding AG (Switzerland), Agilent Technologies (United States), Thermo Fisher Scientific (United States), QIAGEN International (Netherlands), Lonza Group AG (Switzerland), Wuxi Pharmatech (Cayman), Merck (United States), Eurofins Scientific (Luxembourg), General Electric (United States), Danaher Corporation (United States), Bio-Rad Laboratories (United States) and BD (United States). Additionally, following companies can also be profiled that are part of our coverage like Biospherix (United States), Novogene Corporation (China) and Sartorius (Germany). Analyst at AMA Research see United States Players to retain maximum share of Global Viral Testing market by 2027. Considering Market by End-User, the sub-segment i.e. Laboratories will boost the Viral Testing market. Considering Market by Virus Type, the sub-segment i.e. Influenza will boost the Viral Testing market.

What Can be Explored with the Viral Testing Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Viral Testing Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Viral Testing
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Viral Testing market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Viral Testing market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Providers of Viral Testing, End-Users, Potential Investors, Market Research Firms, Regulatory Bodies and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Direct Fluorescent Antibody (DFA) Test
  • Immunochromatographic Assay
  • RT-PCR-Based Test
  • Agglutination Assay
  • Flow-Through Assay/Solid-Phase Assay
By Application
  • Individual
  • Commercial
By End-User
  • Laboratories
  • Hospitals
  • Home Care Settings
  • Academic Institutes

By Virus Type
  • Influenza
  • Hepatitis
  • HIV
  • Measles
  • Rubella
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of the Disease across the Globe
      • 3.2.2. Increasing Demand for More Rapid Diagnostic Test Kits for Influenza
      • 3.2.3. Rising Prevalence of Viral Diseases
    • 3.3. Market Challenges
      • 3.3.1. Unawareness about Viral Testing in Under Developed Regions
    • 3.4. Market Trends
      • 3.4.1. Emergence and Detection of New Viruses
      • 3.4.2. Rising Adoption of Self-Diagnostic and Cost-Effective Test Kits by Patients As Well As Physicians
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Viral Testing, by Type, Application, End-User, Virus Type and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Viral Testing (Value)
      • 5.2.1. Global Viral Testing by: Type (Value)
        • 5.2.1.1. Direct Fluorescent Antibody (DFA) Test
        • 5.2.1.2. Immunochromatographic Assay
        • 5.2.1.3. RT-PCR-Based Test
        • 5.2.1.4. Agglutination Assay
        • 5.2.1.5. Flow-Through Assay/Solid-Phase Assay
      • 5.2.2. Global Viral Testing by: Application (Value)
        • 5.2.2.1. Individual
        • 5.2.2.2. Commercial
      • 5.2.3. Global Viral Testing by: End-User (Value)
        • 5.2.3.1. Laboratories
        • 5.2.3.2. Hospitals
        • 5.2.3.3. Home Care Settings
        • 5.2.3.4. Academic Institutes
      • 5.2.4. Global Viral Testing by: Virus Type (Value)
        • 5.2.4.1. Influenza
        • 5.2.4.2. Hepatitis
        • 5.2.4.3. HIV
        • 5.2.4.4. Measles
        • 5.2.4.5. Rubella
        • 5.2.4.6. Others
      • 5.2.5. Global Viral Testing Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Viral Testing (Volume)
      • 5.3.1. Global Viral Testing by: Type (Volume)
        • 5.3.1.1. Direct Fluorescent Antibody (DFA) Test
        • 5.3.1.2. Immunochromatographic Assay
        • 5.3.1.3. RT-PCR-Based Test
        • 5.3.1.4. Agglutination Assay
        • 5.3.1.5. Flow-Through Assay/Solid-Phase Assay
      • 5.3.2. Global Viral Testing by: Application (Volume)
        • 5.3.2.1. Individual
        • 5.3.2.2. Commercial
      • 5.3.3. Global Viral Testing by: End-User (Volume)
        • 5.3.3.1. Laboratories
        • 5.3.3.2. Hospitals
        • 5.3.3.3. Home Care Settings
        • 5.3.3.4. Academic Institutes
      • 5.3.4. Global Viral Testing by: Virus Type (Volume)
        • 5.3.4.1. Influenza
        • 5.3.4.2. Hepatitis
        • 5.3.4.3. HIV
        • 5.3.4.4. Measles
        • 5.3.4.5. Rubella
        • 5.3.4.6. Others
      • 5.3.5. Global Viral Testing Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Viral Testing (Price)
      • 5.4.1. Global Viral Testing by: Type (Price)
  • 6. Viral Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Roche Holding AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Agilent Technologies (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Thermo Fisher Scientific (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. QIAGEN International (Netherlands)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Lonza Group AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Wuxi Pharmatech (Cayman)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Eurofins Scientific (Luxembourg)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. General Electric (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Danaher Corporation (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Bio-Rad Laboratories (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. BD (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Viral Testing Sale, by Type, Application, End-User, Virus Type and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Viral Testing (Value)
      • 7.2.1. Global Viral Testing by: Type (Value)
        • 7.2.1.1. Direct Fluorescent Antibody (DFA) Test
        • 7.2.1.2. Immunochromatographic Assay
        • 7.2.1.3. RT-PCR-Based Test
        • 7.2.1.4. Agglutination Assay
        • 7.2.1.5. Flow-Through Assay/Solid-Phase Assay
      • 7.2.2. Global Viral Testing by: Application (Value)
        • 7.2.2.1. Individual
        • 7.2.2.2. Commercial
      • 7.2.3. Global Viral Testing by: End-User (Value)
        • 7.2.3.1. Laboratories
        • 7.2.3.2. Hospitals
        • 7.2.3.3. Home Care Settings
        • 7.2.3.4. Academic Institutes
      • 7.2.4. Global Viral Testing by: Virus Type (Value)
        • 7.2.4.1. Influenza
        • 7.2.4.2. Hepatitis
        • 7.2.4.3. HIV
        • 7.2.4.4. Measles
        • 7.2.4.5. Rubella
        • 7.2.4.6. Others
      • 7.2.5. Global Viral Testing Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Viral Testing (Volume)
      • 7.3.1. Global Viral Testing by: Type (Volume)
        • 7.3.1.1. Direct Fluorescent Antibody (DFA) Test
        • 7.3.1.2. Immunochromatographic Assay
        • 7.3.1.3. RT-PCR-Based Test
        • 7.3.1.4. Agglutination Assay
        • 7.3.1.5. Flow-Through Assay/Solid-Phase Assay
      • 7.3.2. Global Viral Testing by: Application (Volume)
        • 7.3.2.1. Individual
        • 7.3.2.2. Commercial
      • 7.3.3. Global Viral Testing by: End-User (Volume)
        • 7.3.3.1. Laboratories
        • 7.3.3.2. Hospitals
        • 7.3.3.3. Home Care Settings
        • 7.3.3.4. Academic Institutes
      • 7.3.4. Global Viral Testing by: Virus Type (Volume)
        • 7.3.4.1. Influenza
        • 7.3.4.2. Hepatitis
        • 7.3.4.3. HIV
        • 7.3.4.4. Measles
        • 7.3.4.5. Rubella
        • 7.3.4.6. Others
      • 7.3.5. Global Viral Testing Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Viral Testing (Price)
      • 7.4.1. Global Viral Testing by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Viral Testing: by Type(USD Million)
  • Table 2. Viral Testing Direct Fluorescent Antibody (DFA) Test , by Region USD Million (2016-2021)
  • Table 3. Viral Testing Immunochromatographic Assay , by Region USD Million (2016-2021)
  • Table 4. Viral Testing RT-PCR-Based Test , by Region USD Million (2016-2021)
  • Table 5. Viral Testing Agglutination Assay , by Region USD Million (2016-2021)
  • Table 6. Viral Testing Flow-Through Assay/Solid-Phase Assay , by Region USD Million (2016-2021)
  • Table 7. Viral Testing: by Application(USD Million)
  • Table 8. Viral Testing Individual , by Region USD Million (2016-2021)
  • Table 9. Viral Testing Commercial , by Region USD Million (2016-2021)
  • Table 10. Viral Testing: by End-User(USD Million)
  • Table 11. Viral Testing Laboratories , by Region USD Million (2016-2021)
  • Table 12. Viral Testing Hospitals , by Region USD Million (2016-2021)
  • Table 13. Viral Testing Home Care Settings , by Region USD Million (2016-2021)
  • Table 14. Viral Testing Academic Institutes , by Region USD Million (2016-2021)
  • Table 15. Viral Testing: by Virus Type(USD Million)
  • Table 16. Viral Testing Influenza , by Region USD Million (2016-2021)
  • Table 17. Viral Testing Hepatitis , by Region USD Million (2016-2021)
  • Table 18. Viral Testing HIV , by Region USD Million (2016-2021)
  • Table 19. Viral Testing Measles , by Region USD Million (2016-2021)
  • Table 20. Viral Testing Rubella , by Region USD Million (2016-2021)
  • Table 21. Viral Testing Others , by Region USD Million (2016-2021)
  • Table 22. South America Viral Testing, by Country USD Million (2016-2021)
  • Table 23. South America Viral Testing, by Type USD Million (2016-2021)
  • Table 24. South America Viral Testing, by Application USD Million (2016-2021)
  • Table 25. South America Viral Testing, by End-User USD Million (2016-2021)
  • Table 26. South America Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 27. Brazil Viral Testing, by Type USD Million (2016-2021)
  • Table 28. Brazil Viral Testing, by Application USD Million (2016-2021)
  • Table 29. Brazil Viral Testing, by End-User USD Million (2016-2021)
  • Table 30. Brazil Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 31. Argentina Viral Testing, by Type USD Million (2016-2021)
  • Table 32. Argentina Viral Testing, by Application USD Million (2016-2021)
  • Table 33. Argentina Viral Testing, by End-User USD Million (2016-2021)
  • Table 34. Argentina Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 35. Rest of South America Viral Testing, by Type USD Million (2016-2021)
  • Table 36. Rest of South America Viral Testing, by Application USD Million (2016-2021)
  • Table 37. Rest of South America Viral Testing, by End-User USD Million (2016-2021)
  • Table 38. Rest of South America Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 39. Asia Pacific Viral Testing, by Country USD Million (2016-2021)
  • Table 40. Asia Pacific Viral Testing, by Type USD Million (2016-2021)
  • Table 41. Asia Pacific Viral Testing, by Application USD Million (2016-2021)
  • Table 42. Asia Pacific Viral Testing, by End-User USD Million (2016-2021)
  • Table 43. Asia Pacific Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 44. China Viral Testing, by Type USD Million (2016-2021)
  • Table 45. China Viral Testing, by Application USD Million (2016-2021)
  • Table 46. China Viral Testing, by End-User USD Million (2016-2021)
  • Table 47. China Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 48. Japan Viral Testing, by Type USD Million (2016-2021)
  • Table 49. Japan Viral Testing, by Application USD Million (2016-2021)
  • Table 50. Japan Viral Testing, by End-User USD Million (2016-2021)
  • Table 51. Japan Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 52. India Viral Testing, by Type USD Million (2016-2021)
  • Table 53. India Viral Testing, by Application USD Million (2016-2021)
  • Table 54. India Viral Testing, by End-User USD Million (2016-2021)
  • Table 55. India Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 56. South Korea Viral Testing, by Type USD Million (2016-2021)
  • Table 57. South Korea Viral Testing, by Application USD Million (2016-2021)
  • Table 58. South Korea Viral Testing, by End-User USD Million (2016-2021)
  • Table 59. South Korea Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 60. Taiwan Viral Testing, by Type USD Million (2016-2021)
  • Table 61. Taiwan Viral Testing, by Application USD Million (2016-2021)
  • Table 62. Taiwan Viral Testing, by End-User USD Million (2016-2021)
  • Table 63. Taiwan Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 64. Australia Viral Testing, by Type USD Million (2016-2021)
  • Table 65. Australia Viral Testing, by Application USD Million (2016-2021)
  • Table 66. Australia Viral Testing, by End-User USD Million (2016-2021)
  • Table 67. Australia Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 68. Rest of Asia-Pacific Viral Testing, by Type USD Million (2016-2021)
  • Table 69. Rest of Asia-Pacific Viral Testing, by Application USD Million (2016-2021)
  • Table 70. Rest of Asia-Pacific Viral Testing, by End-User USD Million (2016-2021)
  • Table 71. Rest of Asia-Pacific Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 72. Europe Viral Testing, by Country USD Million (2016-2021)
  • Table 73. Europe Viral Testing, by Type USD Million (2016-2021)
  • Table 74. Europe Viral Testing, by Application USD Million (2016-2021)
  • Table 75. Europe Viral Testing, by End-User USD Million (2016-2021)
  • Table 76. Europe Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 77. Germany Viral Testing, by Type USD Million (2016-2021)
  • Table 78. Germany Viral Testing, by Application USD Million (2016-2021)
  • Table 79. Germany Viral Testing, by End-User USD Million (2016-2021)
  • Table 80. Germany Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 81. France Viral Testing, by Type USD Million (2016-2021)
  • Table 82. France Viral Testing, by Application USD Million (2016-2021)
  • Table 83. France Viral Testing, by End-User USD Million (2016-2021)
  • Table 84. France Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 85. Italy Viral Testing, by Type USD Million (2016-2021)
  • Table 86. Italy Viral Testing, by Application USD Million (2016-2021)
  • Table 87. Italy Viral Testing, by End-User USD Million (2016-2021)
  • Table 88. Italy Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 89. United Kingdom Viral Testing, by Type USD Million (2016-2021)
  • Table 90. United Kingdom Viral Testing, by Application USD Million (2016-2021)
  • Table 91. United Kingdom Viral Testing, by End-User USD Million (2016-2021)
  • Table 92. United Kingdom Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 93. Netherlands Viral Testing, by Type USD Million (2016-2021)
  • Table 94. Netherlands Viral Testing, by Application USD Million (2016-2021)
  • Table 95. Netherlands Viral Testing, by End-User USD Million (2016-2021)
  • Table 96. Netherlands Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 97. Rest of Europe Viral Testing, by Type USD Million (2016-2021)
  • Table 98. Rest of Europe Viral Testing, by Application USD Million (2016-2021)
  • Table 99. Rest of Europe Viral Testing, by End-User USD Million (2016-2021)
  • Table 100. Rest of Europe Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 101. MEA Viral Testing, by Country USD Million (2016-2021)
  • Table 102. MEA Viral Testing, by Type USD Million (2016-2021)
  • Table 103. MEA Viral Testing, by Application USD Million (2016-2021)
  • Table 104. MEA Viral Testing, by End-User USD Million (2016-2021)
  • Table 105. MEA Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 106. Middle East Viral Testing, by Type USD Million (2016-2021)
  • Table 107. Middle East Viral Testing, by Application USD Million (2016-2021)
  • Table 108. Middle East Viral Testing, by End-User USD Million (2016-2021)
  • Table 109. Middle East Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 110. Africa Viral Testing, by Type USD Million (2016-2021)
  • Table 111. Africa Viral Testing, by Application USD Million (2016-2021)
  • Table 112. Africa Viral Testing, by End-User USD Million (2016-2021)
  • Table 113. Africa Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 114. North America Viral Testing, by Country USD Million (2016-2021)
  • Table 115. North America Viral Testing, by Type USD Million (2016-2021)
  • Table 116. North America Viral Testing, by Application USD Million (2016-2021)
  • Table 117. North America Viral Testing, by End-User USD Million (2016-2021)
  • Table 118. North America Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 119. United States Viral Testing, by Type USD Million (2016-2021)
  • Table 120. United States Viral Testing, by Application USD Million (2016-2021)
  • Table 121. United States Viral Testing, by End-User USD Million (2016-2021)
  • Table 122. United States Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 123. Canada Viral Testing, by Type USD Million (2016-2021)
  • Table 124. Canada Viral Testing, by Application USD Million (2016-2021)
  • Table 125. Canada Viral Testing, by End-User USD Million (2016-2021)
  • Table 126. Canada Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 127. Mexico Viral Testing, by Type USD Million (2016-2021)
  • Table 128. Mexico Viral Testing, by Application USD Million (2016-2021)
  • Table 129. Mexico Viral Testing, by End-User USD Million (2016-2021)
  • Table 130. Mexico Viral Testing, by Virus Type USD Million (2016-2021)
  • Table 131. Viral Testing Sales: by Type(K Units)
  • Table 132. Viral Testing Sales Direct Fluorescent Antibody (DFA) Test , by Region K Units (2016-2021)
  • Table 133. Viral Testing Sales Immunochromatographic Assay , by Region K Units (2016-2021)
  • Table 134. Viral Testing Sales RT-PCR-Based Test , by Region K Units (2016-2021)
  • Table 135. Viral Testing Sales Agglutination Assay , by Region K Units (2016-2021)
  • Table 136. Viral Testing Sales Flow-Through Assay/Solid-Phase Assay , by Region K Units (2016-2021)
  • Table 137. Viral Testing Sales: by Application(K Units)
  • Table 138. Viral Testing Sales Individual , by Region K Units (2016-2021)
  • Table 139. Viral Testing Sales Commercial , by Region K Units (2016-2021)
  • Table 140. Viral Testing Sales: by End-User(K Units)
  • Table 141. Viral Testing Sales Laboratories , by Region K Units (2016-2021)
  • Table 142. Viral Testing Sales Hospitals , by Region K Units (2016-2021)
  • Table 143. Viral Testing Sales Home Care Settings , by Region K Units (2016-2021)
  • Table 144. Viral Testing Sales Academic Institutes , by Region K Units (2016-2021)
  • Table 145. Viral Testing Sales: by Virus Type(K Units)
  • Table 146. Viral Testing Sales Influenza , by Region K Units (2016-2021)
  • Table 147. Viral Testing Sales Hepatitis , by Region K Units (2016-2021)
  • Table 148. Viral Testing Sales HIV , by Region K Units (2016-2021)
  • Table 149. Viral Testing Sales Measles , by Region K Units (2016-2021)
  • Table 150. Viral Testing Sales Rubella , by Region K Units (2016-2021)
  • Table 151. Viral Testing Sales Others , by Region K Units (2016-2021)
  • Table 152. South America Viral Testing Sales, by Country K Units (2016-2021)
  • Table 153. South America Viral Testing Sales, by Type K Units (2016-2021)
  • Table 154. South America Viral Testing Sales, by Application K Units (2016-2021)
  • Table 155. South America Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 156. South America Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 157. Brazil Viral Testing Sales, by Type K Units (2016-2021)
  • Table 158. Brazil Viral Testing Sales, by Application K Units (2016-2021)
  • Table 159. Brazil Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 160. Brazil Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 161. Argentina Viral Testing Sales, by Type K Units (2016-2021)
  • Table 162. Argentina Viral Testing Sales, by Application K Units (2016-2021)
  • Table 163. Argentina Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 164. Argentina Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 165. Rest of South America Viral Testing Sales, by Type K Units (2016-2021)
  • Table 166. Rest of South America Viral Testing Sales, by Application K Units (2016-2021)
  • Table 167. Rest of South America Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 168. Rest of South America Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 169. Asia Pacific Viral Testing Sales, by Country K Units (2016-2021)
  • Table 170. Asia Pacific Viral Testing Sales, by Type K Units (2016-2021)
  • Table 171. Asia Pacific Viral Testing Sales, by Application K Units (2016-2021)
  • Table 172. Asia Pacific Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 173. Asia Pacific Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 174. China Viral Testing Sales, by Type K Units (2016-2021)
  • Table 175. China Viral Testing Sales, by Application K Units (2016-2021)
  • Table 176. China Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 177. China Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 178. Japan Viral Testing Sales, by Type K Units (2016-2021)
  • Table 179. Japan Viral Testing Sales, by Application K Units (2016-2021)
  • Table 180. Japan Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 181. Japan Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 182. India Viral Testing Sales, by Type K Units (2016-2021)
  • Table 183. India Viral Testing Sales, by Application K Units (2016-2021)
  • Table 184. India Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 185. India Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 186. South Korea Viral Testing Sales, by Type K Units (2016-2021)
  • Table 187. South Korea Viral Testing Sales, by Application K Units (2016-2021)
  • Table 188. South Korea Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 189. South Korea Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 190. Taiwan Viral Testing Sales, by Type K Units (2016-2021)
  • Table 191. Taiwan Viral Testing Sales, by Application K Units (2016-2021)
  • Table 192. Taiwan Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 193. Taiwan Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 194. Australia Viral Testing Sales, by Type K Units (2016-2021)
  • Table 195. Australia Viral Testing Sales, by Application K Units (2016-2021)
  • Table 196. Australia Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 197. Australia Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 198. Rest of Asia-Pacific Viral Testing Sales, by Type K Units (2016-2021)
  • Table 199. Rest of Asia-Pacific Viral Testing Sales, by Application K Units (2016-2021)
  • Table 200. Rest of Asia-Pacific Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 201. Rest of Asia-Pacific Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 202. Europe Viral Testing Sales, by Country K Units (2016-2021)
  • Table 203. Europe Viral Testing Sales, by Type K Units (2016-2021)
  • Table 204. Europe Viral Testing Sales, by Application K Units (2016-2021)
  • Table 205. Europe Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 206. Europe Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 207. Germany Viral Testing Sales, by Type K Units (2016-2021)
  • Table 208. Germany Viral Testing Sales, by Application K Units (2016-2021)
  • Table 209. Germany Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 210. Germany Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 211. France Viral Testing Sales, by Type K Units (2016-2021)
  • Table 212. France Viral Testing Sales, by Application K Units (2016-2021)
  • Table 213. France Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 214. France Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 215. Italy Viral Testing Sales, by Type K Units (2016-2021)
  • Table 216. Italy Viral Testing Sales, by Application K Units (2016-2021)
  • Table 217. Italy Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 218. Italy Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 219. United Kingdom Viral Testing Sales, by Type K Units (2016-2021)
  • Table 220. United Kingdom Viral Testing Sales, by Application K Units (2016-2021)
  • Table 221. United Kingdom Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 222. United Kingdom Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 223. Netherlands Viral Testing Sales, by Type K Units (2016-2021)
  • Table 224. Netherlands Viral Testing Sales, by Application K Units (2016-2021)
  • Table 225. Netherlands Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 226. Netherlands Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 227. Rest of Europe Viral Testing Sales, by Type K Units (2016-2021)
  • Table 228. Rest of Europe Viral Testing Sales, by Application K Units (2016-2021)
  • Table 229. Rest of Europe Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 230. Rest of Europe Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 231. MEA Viral Testing Sales, by Country K Units (2016-2021)
  • Table 232. MEA Viral Testing Sales, by Type K Units (2016-2021)
  • Table 233. MEA Viral Testing Sales, by Application K Units (2016-2021)
  • Table 234. MEA Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 235. MEA Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 236. Middle East Viral Testing Sales, by Type K Units (2016-2021)
  • Table 237. Middle East Viral Testing Sales, by Application K Units (2016-2021)
  • Table 238. Middle East Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 239. Middle East Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 240. Africa Viral Testing Sales, by Type K Units (2016-2021)
  • Table 241. Africa Viral Testing Sales, by Application K Units (2016-2021)
  • Table 242. Africa Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 243. Africa Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 244. North America Viral Testing Sales, by Country K Units (2016-2021)
  • Table 245. North America Viral Testing Sales, by Type K Units (2016-2021)
  • Table 246. North America Viral Testing Sales, by Application K Units (2016-2021)
  • Table 247. North America Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 248. North America Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 249. United States Viral Testing Sales, by Type K Units (2016-2021)
  • Table 250. United States Viral Testing Sales, by Application K Units (2016-2021)
  • Table 251. United States Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 252. United States Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 253. Canada Viral Testing Sales, by Type K Units (2016-2021)
  • Table 254. Canada Viral Testing Sales, by Application K Units (2016-2021)
  • Table 255. Canada Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 256. Canada Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 257. Mexico Viral Testing Sales, by Type K Units (2016-2021)
  • Table 258. Mexico Viral Testing Sales, by Application K Units (2016-2021)
  • Table 259. Mexico Viral Testing Sales, by End-User K Units (2016-2021)
  • Table 260. Mexico Viral Testing Sales, by Virus Type K Units (2016-2021)
  • Table 261. Viral Testing: by Type(USD/Units)
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Company Basic Information, Sales Area and Its Competitors
  • Table 268. Company Basic Information, Sales Area and Its Competitors
  • Table 269. Company Basic Information, Sales Area and Its Competitors
  • Table 270. Company Basic Information, Sales Area and Its Competitors
  • Table 271. Company Basic Information, Sales Area and Its Competitors
  • Table 272. Company Basic Information, Sales Area and Its Competitors
  • Table 273. Company Basic Information, Sales Area and Its Competitors
  • Table 274. Viral Testing: by Type(USD Million)
  • Table 275. Viral Testing Direct Fluorescent Antibody (DFA) Test , by Region USD Million (2022-2027)
  • Table 276. Viral Testing Immunochromatographic Assay , by Region USD Million (2022-2027)
  • Table 277. Viral Testing RT-PCR-Based Test , by Region USD Million (2022-2027)
  • Table 278. Viral Testing Agglutination Assay , by Region USD Million (2022-2027)
  • Table 279. Viral Testing Flow-Through Assay/Solid-Phase Assay , by Region USD Million (2022-2027)
  • Table 280. Viral Testing: by Application(USD Million)
  • Table 281. Viral Testing Individual , by Region USD Million (2022-2027)
  • Table 282. Viral Testing Commercial , by Region USD Million (2022-2027)
  • Table 283. Viral Testing: by End-User(USD Million)
  • Table 284. Viral Testing Laboratories , by Region USD Million (2022-2027)
  • Table 285. Viral Testing Hospitals , by Region USD Million (2022-2027)
  • Table 286. Viral Testing Home Care Settings , by Region USD Million (2022-2027)
  • Table 287. Viral Testing Academic Institutes , by Region USD Million (2022-2027)
  • Table 288. Viral Testing: by Virus Type(USD Million)
  • Table 289. Viral Testing Influenza , by Region USD Million (2022-2027)
  • Table 290. Viral Testing Hepatitis , by Region USD Million (2022-2027)
  • Table 291. Viral Testing HIV , by Region USD Million (2022-2027)
  • Table 292. Viral Testing Measles , by Region USD Million (2022-2027)
  • Table 293. Viral Testing Rubella , by Region USD Million (2022-2027)
  • Table 294. Viral Testing Others , by Region USD Million (2022-2027)
  • Table 295. South America Viral Testing, by Country USD Million (2022-2027)
  • Table 296. South America Viral Testing, by Type USD Million (2022-2027)
  • Table 297. South America Viral Testing, by Application USD Million (2022-2027)
  • Table 298. South America Viral Testing, by End-User USD Million (2022-2027)
  • Table 299. South America Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 300. Brazil Viral Testing, by Type USD Million (2022-2027)
  • Table 301. Brazil Viral Testing, by Application USD Million (2022-2027)
  • Table 302. Brazil Viral Testing, by End-User USD Million (2022-2027)
  • Table 303. Brazil Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 304. Argentina Viral Testing, by Type USD Million (2022-2027)
  • Table 305. Argentina Viral Testing, by Application USD Million (2022-2027)
  • Table 306. Argentina Viral Testing, by End-User USD Million (2022-2027)
  • Table 307. Argentina Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 308. Rest of South America Viral Testing, by Type USD Million (2022-2027)
  • Table 309. Rest of South America Viral Testing, by Application USD Million (2022-2027)
  • Table 310. Rest of South America Viral Testing, by End-User USD Million (2022-2027)
  • Table 311. Rest of South America Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 312. Asia Pacific Viral Testing, by Country USD Million (2022-2027)
  • Table 313. Asia Pacific Viral Testing, by Type USD Million (2022-2027)
  • Table 314. Asia Pacific Viral Testing, by Application USD Million (2022-2027)
  • Table 315. Asia Pacific Viral Testing, by End-User USD Million (2022-2027)
  • Table 316. Asia Pacific Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 317. China Viral Testing, by Type USD Million (2022-2027)
  • Table 318. China Viral Testing, by Application USD Million (2022-2027)
  • Table 319. China Viral Testing, by End-User USD Million (2022-2027)
  • Table 320. China Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 321. Japan Viral Testing, by Type USD Million (2022-2027)
  • Table 322. Japan Viral Testing, by Application USD Million (2022-2027)
  • Table 323. Japan Viral Testing, by End-User USD Million (2022-2027)
  • Table 324. Japan Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 325. India Viral Testing, by Type USD Million (2022-2027)
  • Table 326. India Viral Testing, by Application USD Million (2022-2027)
  • Table 327. India Viral Testing, by End-User USD Million (2022-2027)
  • Table 328. India Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 329. South Korea Viral Testing, by Type USD Million (2022-2027)
  • Table 330. South Korea Viral Testing, by Application USD Million (2022-2027)
  • Table 331. South Korea Viral Testing, by End-User USD Million (2022-2027)
  • Table 332. South Korea Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 333. Taiwan Viral Testing, by Type USD Million (2022-2027)
  • Table 334. Taiwan Viral Testing, by Application USD Million (2022-2027)
  • Table 335. Taiwan Viral Testing, by End-User USD Million (2022-2027)
  • Table 336. Taiwan Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 337. Australia Viral Testing, by Type USD Million (2022-2027)
  • Table 338. Australia Viral Testing, by Application USD Million (2022-2027)
  • Table 339. Australia Viral Testing, by End-User USD Million (2022-2027)
  • Table 340. Australia Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 341. Rest of Asia-Pacific Viral Testing, by Type USD Million (2022-2027)
  • Table 342. Rest of Asia-Pacific Viral Testing, by Application USD Million (2022-2027)
  • Table 343. Rest of Asia-Pacific Viral Testing, by End-User USD Million (2022-2027)
  • Table 344. Rest of Asia-Pacific Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 345. Europe Viral Testing, by Country USD Million (2022-2027)
  • Table 346. Europe Viral Testing, by Type USD Million (2022-2027)
  • Table 347. Europe Viral Testing, by Application USD Million (2022-2027)
  • Table 348. Europe Viral Testing, by End-User USD Million (2022-2027)
  • Table 349. Europe Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 350. Germany Viral Testing, by Type USD Million (2022-2027)
  • Table 351. Germany Viral Testing, by Application USD Million (2022-2027)
  • Table 352. Germany Viral Testing, by End-User USD Million (2022-2027)
  • Table 353. Germany Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 354. France Viral Testing, by Type USD Million (2022-2027)
  • Table 355. France Viral Testing, by Application USD Million (2022-2027)
  • Table 356. France Viral Testing, by End-User USD Million (2022-2027)
  • Table 357. France Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 358. Italy Viral Testing, by Type USD Million (2022-2027)
  • Table 359. Italy Viral Testing, by Application USD Million (2022-2027)
  • Table 360. Italy Viral Testing, by End-User USD Million (2022-2027)
  • Table 361. Italy Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 362. United Kingdom Viral Testing, by Type USD Million (2022-2027)
  • Table 363. United Kingdom Viral Testing, by Application USD Million (2022-2027)
  • Table 364. United Kingdom Viral Testing, by End-User USD Million (2022-2027)
  • Table 365. United Kingdom Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 366. Netherlands Viral Testing, by Type USD Million (2022-2027)
  • Table 367. Netherlands Viral Testing, by Application USD Million (2022-2027)
  • Table 368. Netherlands Viral Testing, by End-User USD Million (2022-2027)
  • Table 369. Netherlands Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 370. Rest of Europe Viral Testing, by Type USD Million (2022-2027)
  • Table 371. Rest of Europe Viral Testing, by Application USD Million (2022-2027)
  • Table 372. Rest of Europe Viral Testing, by End-User USD Million (2022-2027)
  • Table 373. Rest of Europe Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 374. MEA Viral Testing, by Country USD Million (2022-2027)
  • Table 375. MEA Viral Testing, by Type USD Million (2022-2027)
  • Table 376. MEA Viral Testing, by Application USD Million (2022-2027)
  • Table 377. MEA Viral Testing, by End-User USD Million (2022-2027)
  • Table 378. MEA Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 379. Middle East Viral Testing, by Type USD Million (2022-2027)
  • Table 380. Middle East Viral Testing, by Application USD Million (2022-2027)
  • Table 381. Middle East Viral Testing, by End-User USD Million (2022-2027)
  • Table 382. Middle East Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 383. Africa Viral Testing, by Type USD Million (2022-2027)
  • Table 384. Africa Viral Testing, by Application USD Million (2022-2027)
  • Table 385. Africa Viral Testing, by End-User USD Million (2022-2027)
  • Table 386. Africa Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 387. North America Viral Testing, by Country USD Million (2022-2027)
  • Table 388. North America Viral Testing, by Type USD Million (2022-2027)
  • Table 389. North America Viral Testing, by Application USD Million (2022-2027)
  • Table 390. North America Viral Testing, by End-User USD Million (2022-2027)
  • Table 391. North America Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 392. United States Viral Testing, by Type USD Million (2022-2027)
  • Table 393. United States Viral Testing, by Application USD Million (2022-2027)
  • Table 394. United States Viral Testing, by End-User USD Million (2022-2027)
  • Table 395. United States Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 396. Canada Viral Testing, by Type USD Million (2022-2027)
  • Table 397. Canada Viral Testing, by Application USD Million (2022-2027)
  • Table 398. Canada Viral Testing, by End-User USD Million (2022-2027)
  • Table 399. Canada Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 400. Mexico Viral Testing, by Type USD Million (2022-2027)
  • Table 401. Mexico Viral Testing, by Application USD Million (2022-2027)
  • Table 402. Mexico Viral Testing, by End-User USD Million (2022-2027)
  • Table 403. Mexico Viral Testing, by Virus Type USD Million (2022-2027)
  • Table 404. Viral Testing Sales: by Type(K Units)
  • Table 405. Viral Testing Sales Direct Fluorescent Antibody (DFA) Test , by Region K Units (2022-2027)
  • Table 406. Viral Testing Sales Immunochromatographic Assay , by Region K Units (2022-2027)
  • Table 407. Viral Testing Sales RT-PCR-Based Test , by Region K Units (2022-2027)
  • Table 408. Viral Testing Sales Agglutination Assay , by Region K Units (2022-2027)
  • Table 409. Viral Testing Sales Flow-Through Assay/Solid-Phase Assay , by Region K Units (2022-2027)
  • Table 410. Viral Testing Sales: by Application(K Units)
  • Table 411. Viral Testing Sales Individual , by Region K Units (2022-2027)
  • Table 412. Viral Testing Sales Commercial , by Region K Units (2022-2027)
  • Table 413. Viral Testing Sales: by End-User(K Units)
  • Table 414. Viral Testing Sales Laboratories , by Region K Units (2022-2027)
  • Table 415. Viral Testing Sales Hospitals , by Region K Units (2022-2027)
  • Table 416. Viral Testing Sales Home Care Settings , by Region K Units (2022-2027)
  • Table 417. Viral Testing Sales Academic Institutes , by Region K Units (2022-2027)
  • Table 418. Viral Testing Sales: by Virus Type(K Units)
  • Table 419. Viral Testing Sales Influenza , by Region K Units (2022-2027)
  • Table 420. Viral Testing Sales Hepatitis , by Region K Units (2022-2027)
  • Table 421. Viral Testing Sales HIV , by Region K Units (2022-2027)
  • Table 422. Viral Testing Sales Measles , by Region K Units (2022-2027)
  • Table 423. Viral Testing Sales Rubella , by Region K Units (2022-2027)
  • Table 424. Viral Testing Sales Others , by Region K Units (2022-2027)
  • Table 425. South America Viral Testing Sales, by Country K Units (2022-2027)
  • Table 426. South America Viral Testing Sales, by Type K Units (2022-2027)
  • Table 427. South America Viral Testing Sales, by Application K Units (2022-2027)
  • Table 428. South America Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 429. South America Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 430. Brazil Viral Testing Sales, by Type K Units (2022-2027)
  • Table 431. Brazil Viral Testing Sales, by Application K Units (2022-2027)
  • Table 432. Brazil Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 433. Brazil Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 434. Argentina Viral Testing Sales, by Type K Units (2022-2027)
  • Table 435. Argentina Viral Testing Sales, by Application K Units (2022-2027)
  • Table 436. Argentina Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 437. Argentina Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 438. Rest of South America Viral Testing Sales, by Type K Units (2022-2027)
  • Table 439. Rest of South America Viral Testing Sales, by Application K Units (2022-2027)
  • Table 440. Rest of South America Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 441. Rest of South America Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 442. Asia Pacific Viral Testing Sales, by Country K Units (2022-2027)
  • Table 443. Asia Pacific Viral Testing Sales, by Type K Units (2022-2027)
  • Table 444. Asia Pacific Viral Testing Sales, by Application K Units (2022-2027)
  • Table 445. Asia Pacific Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 446. Asia Pacific Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 447. China Viral Testing Sales, by Type K Units (2022-2027)
  • Table 448. China Viral Testing Sales, by Application K Units (2022-2027)
  • Table 449. China Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 450. China Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 451. Japan Viral Testing Sales, by Type K Units (2022-2027)
  • Table 452. Japan Viral Testing Sales, by Application K Units (2022-2027)
  • Table 453. Japan Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 454. Japan Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 455. India Viral Testing Sales, by Type K Units (2022-2027)
  • Table 456. India Viral Testing Sales, by Application K Units (2022-2027)
  • Table 457. India Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 458. India Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 459. South Korea Viral Testing Sales, by Type K Units (2022-2027)
  • Table 460. South Korea Viral Testing Sales, by Application K Units (2022-2027)
  • Table 461. South Korea Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 462. South Korea Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 463. Taiwan Viral Testing Sales, by Type K Units (2022-2027)
  • Table 464. Taiwan Viral Testing Sales, by Application K Units (2022-2027)
  • Table 465. Taiwan Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 466. Taiwan Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 467. Australia Viral Testing Sales, by Type K Units (2022-2027)
  • Table 468. Australia Viral Testing Sales, by Application K Units (2022-2027)
  • Table 469. Australia Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 470. Australia Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 471. Rest of Asia-Pacific Viral Testing Sales, by Type K Units (2022-2027)
  • Table 472. Rest of Asia-Pacific Viral Testing Sales, by Application K Units (2022-2027)
  • Table 473. Rest of Asia-Pacific Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 474. Rest of Asia-Pacific Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 475. Europe Viral Testing Sales, by Country K Units (2022-2027)
  • Table 476. Europe Viral Testing Sales, by Type K Units (2022-2027)
  • Table 477. Europe Viral Testing Sales, by Application K Units (2022-2027)
  • Table 478. Europe Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 479. Europe Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 480. Germany Viral Testing Sales, by Type K Units (2022-2027)
  • Table 481. Germany Viral Testing Sales, by Application K Units (2022-2027)
  • Table 482. Germany Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 483. Germany Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 484. France Viral Testing Sales, by Type K Units (2022-2027)
  • Table 485. France Viral Testing Sales, by Application K Units (2022-2027)
  • Table 486. France Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 487. France Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 488. Italy Viral Testing Sales, by Type K Units (2022-2027)
  • Table 489. Italy Viral Testing Sales, by Application K Units (2022-2027)
  • Table 490. Italy Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 491. Italy Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 492. United Kingdom Viral Testing Sales, by Type K Units (2022-2027)
  • Table 493. United Kingdom Viral Testing Sales, by Application K Units (2022-2027)
  • Table 494. United Kingdom Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 495. United Kingdom Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 496. Netherlands Viral Testing Sales, by Type K Units (2022-2027)
  • Table 497. Netherlands Viral Testing Sales, by Application K Units (2022-2027)
  • Table 498. Netherlands Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 499. Netherlands Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 500. Rest of Europe Viral Testing Sales, by Type K Units (2022-2027)
  • Table 501. Rest of Europe Viral Testing Sales, by Application K Units (2022-2027)
  • Table 502. Rest of Europe Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 503. Rest of Europe Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 504. MEA Viral Testing Sales, by Country K Units (2022-2027)
  • Table 505. MEA Viral Testing Sales, by Type K Units (2022-2027)
  • Table 506. MEA Viral Testing Sales, by Application K Units (2022-2027)
  • Table 507. MEA Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 508. MEA Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 509. Middle East Viral Testing Sales, by Type K Units (2022-2027)
  • Table 510. Middle East Viral Testing Sales, by Application K Units (2022-2027)
  • Table 511. Middle East Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 512. Middle East Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 513. Africa Viral Testing Sales, by Type K Units (2022-2027)
  • Table 514. Africa Viral Testing Sales, by Application K Units (2022-2027)
  • Table 515. Africa Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 516. Africa Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 517. North America Viral Testing Sales, by Country K Units (2022-2027)
  • Table 518. North America Viral Testing Sales, by Type K Units (2022-2027)
  • Table 519. North America Viral Testing Sales, by Application K Units (2022-2027)
  • Table 520. North America Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 521. North America Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 522. United States Viral Testing Sales, by Type K Units (2022-2027)
  • Table 523. United States Viral Testing Sales, by Application K Units (2022-2027)
  • Table 524. United States Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 525. United States Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 526. Canada Viral Testing Sales, by Type K Units (2022-2027)
  • Table 527. Canada Viral Testing Sales, by Application K Units (2022-2027)
  • Table 528. Canada Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 529. Canada Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 530. Mexico Viral Testing Sales, by Type K Units (2022-2027)
  • Table 531. Mexico Viral Testing Sales, by Application K Units (2022-2027)
  • Table 532. Mexico Viral Testing Sales, by End-User K Units (2022-2027)
  • Table 533. Mexico Viral Testing Sales, by Virus Type K Units (2022-2027)
  • Table 534. Viral Testing: by Type(USD/Units)
  • Table 535. Research Programs/Design for This Report
  • Table 536. Key Data Information from Secondary Sources
  • Table 537. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Viral Testing: by Type USD Million (2016-2021)
  • Figure 5. Global Viral Testing: by Application USD Million (2016-2021)
  • Figure 6. Global Viral Testing: by End-User USD Million (2016-2021)
  • Figure 7. Global Viral Testing: by Virus Type USD Million (2016-2021)
  • Figure 8. South America Viral Testing Share (%), by Country
  • Figure 9. Asia Pacific Viral Testing Share (%), by Country
  • Figure 10. Europe Viral Testing Share (%), by Country
  • Figure 11. MEA Viral Testing Share (%), by Country
  • Figure 12. North America Viral Testing Share (%), by Country
  • Figure 13. Global Viral Testing: by Type K Units (2016-2021)
  • Figure 14. Global Viral Testing: by Application K Units (2016-2021)
  • Figure 15. Global Viral Testing: by End-User K Units (2016-2021)
  • Figure 16. Global Viral Testing: by Virus Type K Units (2016-2021)
  • Figure 17. South America Viral Testing Share (%), by Country
  • Figure 18. Asia Pacific Viral Testing Share (%), by Country
  • Figure 19. Europe Viral Testing Share (%), by Country
  • Figure 20. MEA Viral Testing Share (%), by Country
  • Figure 21. North America Viral Testing Share (%), by Country
  • Figure 22. Global Viral Testing: by Type USD/Units (2016-2021)
  • Figure 23. Global Viral Testing share by Players 2021 (%)
  • Figure 24. Global Viral Testing share by Players (Top 3) 2021(%)
  • Figure 25. Global Viral Testing share by Players (Top 5) 2021(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Roche Holding AG (Switzerland) Revenue: by Geography 2021
  • Figure 29. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 30. Agilent Technologies (United States) Revenue: by Geography 2021
  • Figure 31. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 32. Thermo Fisher Scientific (United States) Revenue: by Geography 2021
  • Figure 33. QIAGEN International (Netherlands) Revenue, Net Income and Gross profit
  • Figure 34. QIAGEN International (Netherlands) Revenue: by Geography 2021
  • Figure 35. Lonza Group AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. Lonza Group AG (Switzerland) Revenue: by Geography 2021
  • Figure 37. Wuxi Pharmatech (Cayman) Revenue, Net Income and Gross profit
  • Figure 38. Wuxi Pharmatech (Cayman) Revenue: by Geography 2021
  • Figure 39. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 40. Merck (United States) Revenue: by Geography 2021
  • Figure 41. Eurofins Scientific (Luxembourg) Revenue, Net Income and Gross profit
  • Figure 42. Eurofins Scientific (Luxembourg) Revenue: by Geography 2021
  • Figure 43. General Electric (United States) Revenue, Net Income and Gross profit
  • Figure 44. General Electric (United States) Revenue: by Geography 2021
  • Figure 45. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 46. Danaher Corporation (United States) Revenue: by Geography 2021
  • Figure 47. Bio-Rad Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 48. Bio-Rad Laboratories (United States) Revenue: by Geography 2021
  • Figure 49. BD (United States) Revenue, Net Income and Gross profit
  • Figure 50. BD (United States) Revenue: by Geography 2021
  • Figure 51. Global Viral Testing: by Type USD Million (2022-2027)
  • Figure 52. Global Viral Testing: by Application USD Million (2022-2027)
  • Figure 53. Global Viral Testing: by End-User USD Million (2022-2027)
  • Figure 54. Global Viral Testing: by Virus Type USD Million (2022-2027)
  • Figure 55. South America Viral Testing Share (%), by Country
  • Figure 56. Asia Pacific Viral Testing Share (%), by Country
  • Figure 57. Europe Viral Testing Share (%), by Country
  • Figure 58. MEA Viral Testing Share (%), by Country
  • Figure 59. North America Viral Testing Share (%), by Country
  • Figure 60. Global Viral Testing: by Type K Units (2022-2027)
  • Figure 61. Global Viral Testing: by Application K Units (2022-2027)
  • Figure 62. Global Viral Testing: by End-User K Units (2022-2027)
  • Figure 63. Global Viral Testing: by Virus Type K Units (2022-2027)
  • Figure 64. South America Viral Testing Share (%), by Country
  • Figure 65. Asia Pacific Viral Testing Share (%), by Country
  • Figure 66. Europe Viral Testing Share (%), by Country
  • Figure 67. MEA Viral Testing Share (%), by Country
  • Figure 68. North America Viral Testing Share (%), by Country
  • Figure 69. Global Viral Testing: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Roche Holding AG (Switzerland)
  • Agilent Technologies (United States)
  • Thermo Fisher Scientific (United States)
  • QIAGEN International (Netherlands)
  • Lonza Group AG (Switzerland)
  • Wuxi Pharmatech (Cayman)
  • Merck (United States)
  • Eurofins Scientific (Luxembourg)
  • General Electric (United States)
  • Danaher Corporation (United States)
  • Bio-Rad Laboratories (United States)
  • BD (United States)
Additional players considered in the study are as follows:
Biospherix (United States) , Novogene Corporation (China) , Sartorius (Germany)
Select User Access Type

Key Highlights of Report


May 2022 202 Pages 86 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Viral Testing Quantitative research analysis
Global Viral Testing Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Viral Testing market are Roche Holding AG (Switzerland), Agilent Technologies (United States), Thermo Fisher Scientific (United States), QIAGEN International (Netherlands), Lonza Group AG (Switzerland), Wuxi Pharmatech (Cayman), Merck (United States), Eurofins Scientific (Luxembourg), General Electric (United States), Danaher Corporation (United States), Bio-Rad Laboratories (United States) and BD (United States), to name a few.
"Emergence and Detection of New Viruses " is seen as one of major influencing trends for Viral Testing Market during projected period 2021-2027.

Know More About Global Viral Testing Report?

Have a Query? Click Here

Other Related Reports

Luer Lock Comprehensive Study by Type (One Piece Luer Lock, Two-Piece Luer Lock/Rotating Collar Luer Lock), End-User (Hospital, Blood Collection Centers, Diabetic Care Center, Veterinary Care Center,...
$ 3450
Viral Diagnostic Test Kits Comprehensive Study by Type (Influenza Test Kits, Hepatitis Test Kits, Human Immunodeficiency Virus Test Kits, Respiratory Syncytial Virus Test Kits, Other), End Users (Dia...
$ 3750
Nasal Cannula Comprehensive Study by Type (Curved Prong Cannula, Flared Prong Cannula, Curved and Flared Prong Cannula, Straight Prong Cannula), Application (Supplemental Oxygen, Nasal High-flow Ther...
$ 3750
Foley Catheter Comprehensive Study by Type (Two-way Foley Catheter, Three-way Foley Catheter, Four-way Foley Catheter), Application (Urinary Incontinence, Benign Prostatic Hyperplasia, Surgery, Other...
$ 3750
Double J-stent Comprehensive Study by Type (Open End Stents, Double Pigtail Stents, Closed-End Stents, Multiloop Stents), Application (Kidney Stones (Ureteroscopy, Lithotripsy, Percutaneous Nephrolit...
$ 3750
Nebulizer Masks Comprehensive Study by Type (Adult Nebulizer Masks, Kids Nebulizer Masks, Pediatric Nebulizer Masks), End Users (Hospitals, Clinics, Others), Disease Type (Asthma, Cystic Fibrosis, CO...
$ 3650